[go: up one dir, main page]

WO2008152537A3 - Humanized monoclonal antibodies - Google Patents

Humanized monoclonal antibodies Download PDF

Info

Publication number
WO2008152537A3
WO2008152537A3 PCT/IB2008/052038 IB2008052038W WO2008152537A3 WO 2008152537 A3 WO2008152537 A3 WO 2008152537A3 IB 2008052038 W IB2008052038 W IB 2008052038W WO 2008152537 A3 WO2008152537 A3 WO 2008152537A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
mabs
humanized
humanized monoclonal
studies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/052038
Other languages
French (fr)
Other versions
WO2008152537A2 (en
Inventor
Mitali Samaddar
Kemburu Prasanna Kumar
Gosala Jaya Lakshmi
Chigurupati Jayaram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zenotech Laboratories Ltd
Original Assignee
Zenotech Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenotech Laboratories Ltd filed Critical Zenotech Laboratories Ltd
Publication of WO2008152537A2 publication Critical patent/WO2008152537A2/en
Anticipated expiration legal-status Critical
Publication of WO2008152537A3 publication Critical patent/WO2008152537A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Humanized MAbs are designed, created and produced using a series of innovative processes comprising of computational analysis, modeling studies, rationale assessment and selection of humanized sequences, an efficient recombinant DNA expression system and functional studies to interrogate the therapeutic properties of the MAbs. The invention also provides an economic and scalable process of producing the monoclonal antibodies in large quantities and find use in the treatment of human diseases like cancer. Also described is a panel of novel humanized MAbs directed against the human EGFR that acts as receptor antagonists and are substantially non-immunogenic.
PCT/IB2008/052038 2007-06-14 2008-05-23 Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof Ceased WO2008152537A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1236/CHE/2007 2007-06-14
IN1236CH2007 2007-06-14

Publications (2)

Publication Number Publication Date
WO2008152537A2 WO2008152537A2 (en) 2008-12-18
WO2008152537A3 true WO2008152537A3 (en) 2010-04-08

Family

ID=40130263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/052038 Ceased WO2008152537A2 (en) 2007-06-14 2008-05-23 Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof

Country Status (1)

Country Link
WO (1) WO2008152537A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
CA2922562A1 (en) 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114146A (en) * 1994-11-14 2000-09-05 Baxter Aktiengesellschaft Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition
US6602684B1 (en) * 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114146A (en) * 1994-11-14 2000-09-05 Baxter Aktiengesellschaft Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition
US6602684B1 (en) * 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROGUSKA ET AL.: "Humanization of murine monoclonal antibodies through variable domain resurfacing", PNAS, vol. 91, 1994, pages 969 - 973, XP002271704, DOI: doi:10.1073/pnas.91.3.969 *

Also Published As

Publication number Publication date
WO2008152537A2 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
NL301196I2 (en) inebilizumab
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PH12015500782A1 (en) Human cytomegalovirus neutralizing antibodies and use thereof
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
LTC1504035I2 (en) ANTIBODIES SPECIFIC TO HUMAN CD22 AND THEIR THERAPEUTIC AND DIAGNOSTIC USE
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
NZ591471A (en) Antibodies to ccr2
NZ610734A (en) Human antibodies to the glucagon receptor
WO2005012493A3 (en) Anti-cd19 antibodies
MX2010009190A (en) HUMANIZED ANTI-C5aR ANTIBODIES.
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
WO2008066691A3 (en) Tes7 and antibodies that bind thereto
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
EP3539988A3 (en) Monoclonal antibodies against her2
WO2005103081A3 (en) Human monoclonal antibodies against cd20
MY157173A (en) Modified humanised anti-interleukin-18
WO2006089133A3 (en) Anti-cd19 antibodies and uses in oncology
MX355256B (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof.
WO2011044311A3 (en) Generation, characterization and uses thereof of anti-her 3 antibodies
DOP2009000221A (en) UNION PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, WHICH SPECIFICALLY JOIN CD154 AND ITS USES
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08751313

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08751313

Country of ref document: EP

Kind code of ref document: A2